Article
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Blood
(2017)
Disciplines
Publication Date
December 7, 2017
DOI
10.1182/BLOOD.V130.SUPPL_1.637.637
Citation Information
Geoffrey L. Uy, John Godwin, Michael P Rettig, Norbert Vey, et al.. "Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" Blood Vol. 130 (2017) p. 637 - 637 Available at: http://works.bepress.com/carlo-bifulco/71/